Form 4: Glucotrack Insider John A. Ballantyne Revocable Living Trust Reports Significant Stock and Warrant Transactions
SEC Form 4 Filing
John A. Ballantyne Revocable Living Trust reports acquisition and disposal of Glucotrack, Inc. stock and warrants following debt conversion and cashless warrant exercise.
Summary
- On July 30, 2024, the John A. Ballantyne Revocable Living Trust entered into a convertible promissory note and warrant agreements with Glucotrack, Inc. for a $4,000,000 private placement.
- On November 14, 2024, the Ballantyne Trust converted approximately $4,093,112 of debt into 132,036 shares of common stock, plus Series A and Series B common warrants, at a conversion price of $31.00 per share.
- Also on November 14, 2024, the Ballantyne Trust received 132,036 Series A and 132,036 Series B common warrants, each with an exercise price of $5.60 per share.
- On March 12, 2025, the Ballantyne Trust exercised the Series B Common Warrants on a cashless basis, receiving 2,560,553 shares of common stock.
- The report reflects a 1-for-5 reverse stock split implemented on May 17, 2024, and a 1-for-20 reverse stock split implemented on February 25, 2025.
Sentiment
Score: 5
Explanation: The document primarily reports transactions. The reverse stock splits could be a concern, but the debt conversion and warrant exercises are standard financial activities.
Industry Context
This Form 4 filing reflects insider activity related to debt conversion and warrant exercises, which are common financial maneuvers for companies, particularly smaller ones, seeking capital. The reverse stock splits suggest the company may have been struggling to maintain listing requirements.
Related Party Transactions
- The transactions involve the John A. Ballantyne Revocable Living Trust, an entity with a relationship to the issuer.
Stakeholder Impact
- The debt conversion and warrant exercises dilute existing shareholders' equity.
- The reverse stock splits may impact the perceived value and trading liquidity of the stock.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | 1-for-5 reverse stock split implemented |
| 07/30/2024 | Issuer entered into a convertible promissory note and warrant agreements with the Ballantyne Trust |
| 11/12/2024 | Day prior to the date the securities purchase agreement governing the Conversion was executed |
| 11/14/2024 | Ballantyne Trust converted debt into 132,036 shares and received warrants; public offering completed |
| 02/25/2025 | 1-for-20 reverse stock split implemented |
| 03/12/2025 | Ballantyne Trust exercised Series B Common Warrants on a cashless basis |
| 03/31/2025 | Date of signature for the Form 4 filing |
Keywords
Form 4, insider trading, warrants, debt conversion, reverse stock split, GCTK, Glucotrack, Ballantyne Trust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.